Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer

Cancer Immunology, Immunotherapy

Volumn 61, Issue 12, 2012, Pages 2251-2259

  Shi, Liangrong ^a   Zhou, Qi ^a   Wu, Jun ^a   Ji, Mei ^a   Li, Guojun ^b   Jiang, Jingting ^a   Wu, Changping ^a  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant; Chemotherapy; Cytokine induced killer cells; Gastric cancer; Immunotherapy

Indexed keywords

ANTIALLERGIC AGENT; ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL; OXALIPLATIN;

ABNORMAL LABORATORY RESULT; ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CHILL; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DIARRHEA; DISEASE FREE SURVIVAL; FEMALE; FEVER; FOLLOW UP; GASTRECTOMY; HEADACHE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY DISEASE; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; RECURRENCE RISK; SHOCK; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING;

ANTIGENS, CD; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; STOMACH NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 84870988226     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1289-2     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Sun XD, Mu R, Zhou YS, Dai XD, Zhang SW, Huangfu XM et al (2004) Analysis of mortality rate of stomach cancer and its trend in twenty years in China. Zhonghua Zhong Liu Za Zhi 26:4-9
3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
5. Bouche O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G et al (2005) Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 16:1488-1497
6. Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E et al (2010) Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: A pilot study. Arch Surg 145:233-238
7. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y et al (2003) Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 21:2282-2287
8. Kodera Y, Fujiwara M, Koike M, Nakao A (2006) Chemotherapy as a component of multimodal therapy for gastric carcinoma. World J Gastroenterol 12:2000-2005
9. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P et al (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353-362
10. Rayman P, Uzzo RG, Kolenko V, Bloom T, Cathcart MK, Molto L et al (2000) Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: A mechanism of immune escape. Cancer J Sci Am 6(Suppl 1):S81-S87
11. Cho MY, Joh YG, Kim NR, Jung SI, Bae JW, Kim YC et al (2002) T-lymphocyte subsets in patients with AJCC stage III gastric cancer during postoperative adjuvant chemotherapy. American Joint Committee on Cancer. Scand J Surg 91:172-177
12. Cole WH, Humphrey L (1985) Need for immunologic stimulators during immunosuppression produced by major cancer surgery. Ann Surg 202:9-20
13. Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, Lindblad R et al (2010) Developments in clinical cell therapy. Cytotherapy 12:425-428
14. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG (2011) Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137:305-310
15. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX et al (2008) Minimally invasive treatment combined with cytokineinduced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 31:63-71
16. Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M (2004) Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 7:240-245
17. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2007) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56:905-911
18. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343:1122-1126
19. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y (2003) A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma. Hepatogastroenterology 50:2259-2263
20. Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T et al (2002) Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: A meta-analysis of centrally randomized controlled clinical trials. J Immunother 25:405-412
21. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139-149
22. Verneris MR, Kornacker M, Mailander V, Negrin RS (2000) Resistance of ex vivo expanded CD3? CD56? T cells to Fasmediated apoptosis. Cancer Immunol Immunother 49:335-345
23. Li HF, Yang YH, Shi YJ, Wang YQ, Zhu P (2004) Cytokineinduced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA. Chin Med J (Engl) 117:1348-1352
24. Jiang J, Xu N,Wu C, Deng H, LuM, LiMet al (2006) Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 26:2237-2242
25. Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG (1997) Activated T cells and cytokine-induced CD3? CD56? killer cells. Ann Hematol 74:51-56
26. Wu C, Jiang J, Shi L, Xu N (2008) Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28:3997-4002
27. Rosenberg S (1985) Lymphokine-activated killer cells: A new approach to immunotherapy of cancer. J Natl Cancer Inst 75:595-603
28. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
29. Yun YS, Hargrove ME, Ting CC (1989) In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 49:4770-4774
30. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS (1994) Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 87:453-458
31. VernerisMR, Ito M, Baker J,Arshi A, Negrin RS, Shizuru JA (2001) Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8? NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 7:532-542
32. Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA et al (1996) Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 169:85-90
33. Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E et al (2006) Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol 80:1345-1353
34. Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB et al (2002) Antitumor activities of human autologous cytokineinduced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 8:464-468
35. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2004) Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10:1146-1151
36. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY et al (2001) Survival and prognostic factors for gastric cancer. Analysis of 2,334 patients. Med Clin (Barc) 117:361-365
37. Guglielmi A, de Manzoni G, Tomezzoli A, Ricci F, Pelosi G, Laterza E et al (1997) Prognostic value of histologic classifications of advanced stomach cancer: Comparative study of Lauren's and Goseki's classifications. Chir Ital 49:45-49
38. Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L et al (2002) Different patterns of recurrence in gastric cancer depending on Lauren's histological type: Longitudinal study. World J Surg 26:1160-1165
39. Von Roenn J, Harris JE, Braun DP (1987) Suppressor cell function in solid tumor cancer patients. J Clin Oncol 5:150-159
40. Robinson E, Segal R, Struminger L, Faraggi D, El'ad-Yarum R, Mekori T (1999) Lymphocyte subpopulations in patients with multiple primary tumors. Cancer 85:2073-2076